The decline in cervical cancer is a success story of cancer research. Although there are reasons to be optimistic about even further decreases in cervical cancer incidence, there still remain some women who are not screened. A meta-analysis by Spence and colleagues published in the August-September 2007 issue of Preventive Medicine shows that undergoing Pap smears irregularly or never was the primary explanation for the development of invasive cervical cancer, followed by false negative tests and poor follow-up of abnormal results.
Papanicolaou and Traut first reported the usefulness of the Papanicolaou smear (''Pap test") for detecting neoplastic cervical cells in 1943. A smear of cells of the uterine cervix indicating the progression of the cancer's growing malignity provided a powerful screening tool that became rapidly used after WWII without its efficacy being evaluated in a randomized control trial.
In the United States, the Pap test is credited with having halved the annual cervical cancer incidence rate (from 17.2 to 8.0 per 100,000) and mortality rate (from 6.2 to 2.9) from 1973 to 1999. In 2000, 83% of U.S. women age 18 and older who had not had a hysterectomy reported having had a Pap test within the past 3 years. The recent discovery of a vaccine against human papillomavirus (HPV), the main cause of cervical cancer, opens the way to the primary prevention of the disease.
The natural history of cervical cancer progression combined with the availability of an HPV vaccine and an effective screening test indicate that eradication of the disease is a plausible objective. To reach that goal, however, it is important not to give up on the minority of women who do not fully benefit from available prevention methods and unfortunately fail to be reached by health promotion messages.
Dr. Eduardo Franco, the study’s principal investigator, commented on the findings: “Cervical cancer is a sentinel disease of inequity. The socio-economic disparity already seen with availability of screening could aggravate if vaccination fails to reach the daughters of women at greatest risk. Like mothers, like daughters; the latter unvaccinated and unprotected by screening will eventually contribute to the sad reality of cervical cancer statistics in the future. The solution is to adopt vaccination and screening as universal strategies, with the latter modified to make cost-effective use of limited resources.”
Source: Elsevier
Related stories:
Want a mammogram? Get in line
Doctors usually recommend that women older than 40 get yearly mammograms. But if you're planning on calling Northwestern Memorial Hospital's state-of-the-art breast imaging center, grab next year's calendar: The next opening is in May.
Social class dictates cancer risk
Cervical and lung cancer are more common in poor people while rates of breast cancer and melanoma are higher in the wealthy. A detailed analysis of the incidence of these four different kinds of cancer, carried out on more than 300,000 English cancer patients and published today in the open access journal
BMC Cancer, describes the effects of socioeconomic group, region and age.
Link between nationality and cervical cancer
Gynaecological screening tests for cervical cancer have been available to all women in Sweden for almost four decades. Despite this, many immigrant women have a higher risk of developing the disease than Swedish-born women, according to a new study from the medical university Karolinska Institutet.
Cervical cancer prevention should focus on vaccinating adolescent girls
The cost-effectiveness of vaccination in the United States against human papillomavirus (HPV), a sexually-transmitted virus that causes cervical cancer, will be optimized by achieving universal vaccine coverage in young adolescent girls, by targeting initial "catch-up" efforts to vaccinate women younger than 21 years of age, and by revising current screening policies, according to an analysis by Harvard School of Public Health (HSPH) researchers in the August 21, 2008 issue of
The New England Journal of Medicine.
Study on government's controversial choice of HPV vaccine
The UK government may save up to £18.6 million a year by deciding to use the HPV vaccine Cervarix, given that it is equally effective as the more expensive Gardasil in preventing cervical abnormalities, according to a study published on BMJ.com today.
Analysis of cancer incidence, mortality and survival combined reveals encouraging European trends
The first research to look at recent trends in European cancer incidence, mortality and survival together has shown that cancer prevention and management in Europe is moving in the right direction. However, the research reveals that variations between countries in policies for mass screening, access to health care and treatment are reflected in the different cancer rates.
Only 1 in 5 women in developing world receive effective cervical cancer screening
Few women in the developing world are screened effectively for cervical cancer and those at highest risk of developing the disease are among the least likely to be screened, accordingly an analysis published in
PLoS Medicine. The study, by Emmanuela Gakidou (University of Washington, Seattle, USA) and colleagues, also finds striking inequalities in access to cervical cancer screening between and within countries.
Obese women in Canada are less likely to be screened for cervical cancer
Research in the United States has shown that obese people are less likely than their normal-weight peers to undergo screening for breast, colon and cervical cancer. Raj Padwal, Rebecca Mitchell and Scott Klarenbach, from the University of Alberta's Faculty of Medicine & Dentistry, have undertaken a study to see if this trend is also true in Canada.